Search results
Body
Showing 1-10 of 252 results
Saint Luke's cardiologists and surgeons perform the full spectrum of surgical cardiovascular interventions.
Saint Luke's cardiovascular surgical teams perform the full spectrum of surgical cardiovascular interventions.
Adults with obesity-related heart failure and diabetes saw improvements in heart failure symptoms and physical function with semaglutide 2.4 mg compared with placebo, a recent study showed.
The University of Missouri – Kansas City School of Medicine’s Cardiovascular Disease Fellowship in partnership with Saint Luke’s Mid America Heart Institute has been named one of the 10 best cardiology training programs in the United States based on national In-Training Examination performance.
The Saint Luke’s Michael and Marlys Haverty Cardio Metabolic Center of Excellence is a new clinic designed to provide comprehensive risk reduction, by focusing on the prevention and treatment of heart complications in people with type 2 diabetes.
The treatment of CAD in patients with type 2 diabetes may need to be more aggressive compared with those without diabetes to reduce the risk for MI and other complications. Dr. Suzanne Arnold explains why in Cardiology Today.
Cardiovascular Business spoke with Dr. Timothy Bateman about his views on SPECT advances and its longevity in the coming years.
Saint Luke’s Mid America Heart Institute to share detailed trial results at American College of Cardiology Scientific Session May 15-17.
Dr. Mikhail Kosiborod reviewed research at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease on the cardiovascular benefits of Ozempic/Wegovy for adults with obesity.
A new groundbreaking study is helping cardiologists across the globe to better understand and provide the most suitable treatments for their patients. KCUR talks to Dr. John Spertus about the practice-changing trial.